Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$187.06 +0.9%	$186.03	$163.52 ▼ $218.66	$327.47B	0.5	6.23 million shs	5.73 million shs
AZN AstraZeneca	$70.07 +0.6%	$70.55	$61.24 ▼ $87.68	$216.10B	0.38	5.22 million shs	4.25 million shs
NVS Novartis	$120.36 +2.0%	$113.76	$96.06 ▼ $120.92	$249.27B	0.59	1.58 million shs	1.64 million shs
PFE Pfizer	$24.30 +0.2%	$23.42	$20.92 ▼ $31.54	$137.93B	0.57	41.30 million shs	31.72 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.76%	+0.97%	+0.83%	-8.80%	+9.30%
AZN AstraZeneca	+0.56%	-0.98%	-1.25%	-5.04%	-11.39%
NVS Novartis	+2.06%	+3.78%	+6.48%	+6.80%	+12.36%
PFE Pfizer	+0.06%	+1.80%	+2.94%	-3.56%	-11.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9438 of 5 stars	3.4	5.0	4.2	3.9	3.0	2.5	1.3
AZN AstraZeneca	2.8321 of 5 stars	2.4	5.0	1.7	0.0	2.9	0.0	1.3
NVS Novartis	1.5266 of 5 stars	1.0	4.0	2.5	0.0	2.9	0.0	1.3
PFE Pfizer	4.8943 of 5 stars	2.3	4.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	12.95% Upside
AZN AstraZeneca	2.83	Moderate Buy	$85.00	21.31% Upside
NVS Novartis	2.00	Hold	$123.38	2.51% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.01% Upside

Current Analyst Ratings Breakdown

Latest NVS, AZN, PFE, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/22/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$210.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$214.00 ➝ $214.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.87	$15.06 per share	12.42	$1.90 per share	98.45
AZN AstraZeneca	$54.07B	4.02	$6.33 per share	11.07	$13.18 per share	5.32
NVS Novartis	$50.32B	5.05	$10.91 per share	11.03	$21.59 per share	5.57
PFE Pfizer	$63.63B	2.17	$4.37 per share	5.56	$15.62 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	79.60	13.38	1.23	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.14	14.01	1.28	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.81	13.66	1.70	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.61	8.02	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest NVS, AZN, PFE, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/24/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	N/A	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.51%	N/A	279.15%	53 Years
AZN AstraZeneca	$2.06	2.94%	N/A	82.73%	N/A
NVS Novartis	$2.60	2.16%	N/A	40.63%	N/A
PFE Pfizer	$1.72	7.08%	N/A	124.64%	16 Years

Latest NVS, AZN, PFE, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
AZN AstraZeneca	0.65	0.90	0.70
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AZN AstraZeneca	20.35%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AZN AstraZeneca	N/A
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

NVS, AZN, PFE, and ABBV Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Announces Positive Results For Hemophilia Treatment And Declares $0.43 Dividend

5 hours ago | uk.finance.yahoo.com

Pfizer releases positive Hympavzi Phase III results in hemophilia

5 hours ago | thepharmaletter.comT

Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodies

5 hours ago | msn.com

All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy

June 26 at 1:01 PM | zacks.com

Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment

June 26 at 12:40 PM | tipranks.com

Pfizer’s Promising Clinical Trial for Relapsed Refractory Multiple Myeloma

June 26 at 12:40 PM | tipranks.com $https://www.tipranks.com/news/company-announcements/pfizers-promising-clinical-trial-for-relapsed-refractory-multiple-myeloma?utm_source=marketbeat.com&utm_medium=referral$

Pfizer’s Promising Phase 3 Study on Rimegepant for Menstrual Migraine Prevention

June 26 at 12:40 PM | tipranks.com

Pfizer’s Promising Phase 3 Trial: A New Hope for Multiple Myeloma Treatment

June 26 at 12:40 PM | tipranks.com

Pfizer’s Promising Pediatric Migraine Study: A Potential Game-Changer?

June 26 at 12:40 PM | tipranks.com

Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies

June 26 at 7:23 AM | reuters.com

Sabal Trust CO Has $21.23 Million Position in Pfizer Inc. (NYSE:PFE)

June 26 at 6:51 AM | marketbeat.com

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

June 26 at 6:45 AM | businesswire.com

Robeco Institutional Asset Management B.V. Purchases 1,053,482 Shares of Pfizer Inc. (NYSE:PFE)

June 26 at 6:42 AM | marketbeat.com

Phillips Wealth Planners LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

June 26 at 5:58 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Inman Jager Wealth Management LLC

June 26 at 5:57 AM | marketbeat.com

Golden State Wealth Management LLC Buys 33,176 Shares of Pfizer Inc. (NYSE:PFE)

June 26 at 5:31 AM | marketbeat.com

Aurora Private Wealth Inc. Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

June 26 at 5:21 AM | marketbeat.com

Ursula von der Leyen faces no-confidence vote over Pfizergate

June 26 at 2:20 AM | ft.com

Pfizer Could Be The Turnaround Story In The Pharmaceutical Space

June 25 at 12:04 AM | seekingalpha.com

Golden Crossovers: These 6 stocks signal bullishness on June 26

June 25 at 11:15 PM | economictimes.indiatimes.com

Pfizer Inc. (NYSE:PFE) Announces Quarterly Dividend of $0.43

June 25 at 7:23 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS, AZN, PFE, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$187.06 +1.67 (+0.90%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$187.40 +0.34 (+0.18%)

As of 06/26/2025 07:47 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$70.07 +0.39 (+0.56%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$70.10 +0.04 (+0.05%)

As of 06/26/2025 07:51 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novartis NYSE:NVS

$120.36 +2.36 (+2.00%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$120.26 -0.10 (-0.08%)

As of 06/26/2025 07:39 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$24.30 +0.04 (+0.18%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$24.26 -0.04 (-0.16%)

As of 06/26/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time